Therapeutic Advances in Infectious Disease
tainfdis.bsky.social
Therapeutic Advances in Infectious Disease
@tainfdis.bsky.social
🦠🚀 High-impact infectious disease research—Rigorous in review, Global in impact. Gold open access and indexed in PubMed, Scopus, and ESCI.
Novel entomo-virological tools, such as honey-baited traps preserving mosquito-expectorated RNA, are reshaping arbovirus monitoring. Integrating these with genomic surveillance can bridge field ecology and molecular epidemiology. 🔬🦟https://journals.sagepub.com/doi/full/10.1177/20499361251391261
November 2, 2025 at 5:05 PM
P. aeruginosa is the archetype of adaptive resistance—porins close, pumps activate, enzymes evolve. New β-lactam/β-lactamase inhibitor combos and cefiderocol offer treatment options.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 30, 2025 at 1:19 PM
📈 Retrospective time-series study (2014–2019, Mysuru, India):
Rising temperature, humidity, and monsoon rainfall were linked to increased Salmonella bacteraemia.
Findings suggest climate–infection interplay with implications for AMR trends.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 28, 2025 at 1:10 PM
Meta-analysis (7 studies, n=1685): Cefazolin vs. ASPs for MSSA endocarditis — similar efficacy, lower 30-day mortality (OR 0.49, 95% CI 0.29–0.83), and fewer adverse events. Supports cefazolin as a viable alternative
journals.sagepub.com/doi/full/10....
Comparative effectiveness of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a systematic review of observational studies - Lau...
Background: Methicillin-susceptible Staphylococcus aureus (MSSA) is a leading cause of infective endocarditis (IE), associated with high morbidity and mortality...
journals.sagepub.com
October 28, 2025 at 1:08 PM
🚨study from Bolivia: A novel PCR platform—Orange G3 TBC—shows comparable accuracy to GeneXpert Ultra for TB diagnosis (sensitivity = 90%, specificity = 97%). Its biosafe, low-resource–friendly design could expand TB testing access in endemic settings.
journals.sagepub.com/doi/full/10....
Diagnostic accuracy of the novel and biosafe molecular assay Orange G3 TBC compared to GeneXpert for tuberculosis diagnosis in resource-limited settings - Juan Carlos Garberi, Gabriel Estryk, Richard ...
Background: Tuberculosis (TB) remains a global public health priority, with 10.5 million new cases and 1.5 million deaths reported in 2023. Current diagnostic m...
journals.sagepub.com
October 22, 2025 at 12:47 PM
Excited to see everyone at #IDWeek2025! Catch the @TAInfDis team sharing insights across these great sessions.
October 20, 2025 at 10:54 AM
A systematic review (2003–2023) shows live attenuated (LAIV) and inactivated (IIV) influenza vaccines protect children/adolescents equally well (~50% VE). Post-2017 LAIV strain updates restored H1N1 protection and improved efficacy vs influenza B.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 18, 2025 at 2:32 PM
In a survey of 128 HIV care workers, negative attitudes toward people who use drugs were strongly linked to lower acceptance of harm reduction practices. Acceptance varied by site, race, and experience—pointing to structural and training gaps.
journals.sagepub.com/doi/full/10....
Attitudes of HIV healthcare Provider Attitudes Towards PWH who use Drugs and acceptance of harm reduction strategies: a cross-sectional study - Rabab F. M. Ahmed, Robert W. S. Coulter, M. Reuel Friedm...
Background: Negative attitudes toward people who use drugs (PWUD) can hinder their engagement in healthcare and contribute to poor clinical outcomes. While harm...
journals.sagepub.com
October 15, 2025 at 1:02 PM
Dolutegravir/lamivudine improved quality of life, treatment acceptability, and symptom burden in PLWH over 6 months (French multicenter study, n=260). Gains appeared by month 1 and persisted. Monitoring discontinuations—especially among women—remains key.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 15, 2025 at 12:59 PM
Systematic review/meta-analysis (2013–2024, n=23,319): In febrile neutropenia after chemotherapy, bloodstream infections were 59% Gram-negative, 39.7% Gram-positive, and 2.5% fungal.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 10, 2025 at 12:41 PM
The Clade IIb #mpox 🌍 outbreak exposed major gaps in evidence for antivirals 💊, vaccine equity 💉, and surveillance. This review maps the path toward targeted, evidence-based treatments and prevention✨
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 7, 2025 at 1:13 PM
ED study in Japan: Relaxation of COVID-19 IPC practices led to a surge in virus-related exacerbations of COPD (7.7%→52.5%) & asthma (39.7%→66.7%). Reinforcing viral prevention is key in chronic airway disease care.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 2, 2025 at 2:36 PM
📊 HIV from injection drug use is climbing (2016–2022).
PrEP uptake in PWID remains critically low.
Call to action: integrate ID + addiction care, expand low-barrier services, implement LA-PrEP, and fight stigma through policy + education.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 2, 2025 at 2:34 PM
Hospital clinician training transformed care for PWUD w/ severe infections. Post-training: 95% applied harm reduction (vs 55%), 69% discussed safer use (vs 38%).
journals.sagepub.com/doi/full/10....
A descriptive survey evaluating the implementation and outcomes of a training session highlighting concepts in antimicrobial management and harm reduction for hospital-based clinicians treating person...
Background: People who use drugs (PWUD) are at increased risk for severe infections and face many barriers when completing conventional, typically parenteral an...
journals.sagepub.com
September 23, 2025 at 1:42 PM
East Jerusalem hospital study (2019–2023): CRE in 20.6% of Enterobacterales isolates; blaNDM dominated (82%), blaOXA-48 (13%). Prevalence rising, Klebsiella most common. journals.sagepub.com/doi/full/10....
Prevalence, molecular carbapenemase detection, and antibiotic resistance of carbapenem-resistant Enterobacterales in a tertiary care hospital in East Jerusalem (2019–2023): a retrospective study - Lil...
Background: Carbapenem-resistant Enterobacterales (CRE) are a significant public health threat affecting human health globally. Unfortunately, the incidence of ...
journals.sagepub.com
September 15, 2025 at 3:25 PM
Despite free HIV care & PrEP in Peru, HIV incidence among youth remains high (13% at age 18; 25% in trans youth <18). Restricting PrEP to 18+ misses a critical window. Peru must expand PrEP to 15–17-year-olds.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
September 12, 2025 at 11:24 AM
In CNS neuroimmunological disease, anti-CD20/S1PRM therapies blunt humoral responses even after 4th SARS-CoV-2 vaccine dose or breakthrough infection. Encouragingly, no evidence of intermediate-term neuroinflammation or neural injury post-COVID-19
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
September 10, 2025 at 1:23 PM
Rare case: concurrent Mycobacterium avium & M. kansasii infection in a patient w/ MDS & germline GATA2, on cobimetinib. Suggests profound susceptibility to NTM & therapeutic challenges in this setting.
journals.sagepub.com/doi/10.1177/...
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
September 7, 2025 at 5:20 AM
Real-world fascioliasis data (174 pts, TriNetX 2021–24): common comorbidities, GI symptoms, biliary complications in ~10%, 90-day mortality <6%. Triclabendazole reported in just 6%—access or reporting gap? Prospective studies needed
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
September 7, 2025 at 5:16 AM
UTIs drive huge antimicrobial use worldwide. This editorial highlights innovations—PCR, AMR surveillance, PROMs—to guide sustainable, patient-centred therapy.
journals.sagepub.com/doi/full/10....
journals.sagepub.com
September 4, 2025 at 7:13 AM
🧪 Meta-analysis of 5,399 patients: RA patients show TNF-α levels comparable to those in sepsis.
⚠️ Anti-TNF therapy works in RA but not sepsis → TNF-α unlikely to be central in sepsis biology.
journals.sagepub.com/doi/full/10....
journals.sagepub.com
September 2, 2025 at 4:42 PM
Chikungunya: a strong contender for Disease X.
✔ Key mutations drive rapid spread
✔ Debilitating chronic disease + neonatal risk
✔ Vaccine inequity, no treatment
✔ Climate & travel accelerate reach
Global vigilance is critical.
journals.sagepub.com/doi/full/10....
Chikungunya virus: from genetic adaptation to pandemic risk and prevention - Shoubeho Sadique Shandhi, Suprety Malaker, Mohammad Shahriar, Ramisa Anjum, 2025
Chikungunya virus (CHIKV) has emerged as a serious candidate for “Disease X”—the name for an unknown agent that could cause a global pandemic. This paper search...
journals.sagepub.com
August 31, 2025 at 7:16 AM
🇻🇳 Cross-sectional study of 876 pregnant women in Hanoi: GBS colonization prevalence 19.5%. Independent risk factors: higher education & yellow vaginal discharge. Predominant serotypes: III, V, VI.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
August 18, 2025 at 11:35 AM
💉 Bloodstream infections from carbapenemase-producing Enterobacterales in acute leukemia carry high mortality (~61%). In a Peruvian cohort, use of ceftazidime–avibactam cut 30-day mortality risk by 70% vs. other therapies (aHR 0.29, 95% CI 0.09–0.92).
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
August 17, 2025 at 5:39 AM
💉 “Tranq” (xylazine) + fentanyl → rising overdoses, devastating necrotic wounds, & systemic infections. This vignette shows why new harm reduction tools like drug-checking are urgently needed.
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
August 16, 2025 at 9:46 AM